دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Thanks to Referees 2022
doi : 10.1016/j.annonc.2022.10.505
Volume 34, Issue 1, January 2023, Pages 1-3
Rules for the conduct of clinical trials need revision, but ‘good clinical practice’ requires much more
A. Salawu & I. F. Tannock
doi : 10.1016/j.annonc.2022.10.005
Volume 34, Issue 1, January 2023, Pages 4-6
COP27 Climate Change Conference: urgent action needed for Africa and the world
L. Atwoli 1 , G. E. Erhabor 2 , A. A. Gbakima3 , A. Haileamlak 4 , J.-M. Kayembe Ntumba 5 , J. Kigera6 , L. Laybourn-Langton 7 , B. Mash 8 , J. Muhia 9 , F. M. Mulaudzi 10 , D. Ofori-Adjei 11 , F. Okonofua 12 , A. Rashidian 13 , M. El-Adawy 13 , S. Sidibé 14 , A. Snouber15 , J. Tumwine 16 , M. S. Yassien17 , P. Yonga1 , L. Zakhama18 & C. Zielinski
doi : 10.1016/j.annonc.2022.10.504
Volume 34, Issue 1, January 2023, Pages 7-9
Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
A. Cervantes 1,2 , R. Adam 3 , S. Roselló 1,2 , D. Arnold 4 , N. Normanno5 , J. Taïeb 6,7 , J. Seligmann8 , T. De Baere 9,10,11 , P. Osterlund12,13 , T. Yoshino 14 & E. Martinelli 15 , on behalf of the ESMO Guidelines Committee
doi : 10.1016/j.annonc.2022.10.003
Volume 34, Issue 1, January 2023, Pages 10-32
Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline
C. Sessa 1 , J. Balmaña 2 , S. L. Bober3 , M. J. Cardoso4 , N. Colombo 5,6 , G. Curigliano 7,8 , S. M. Domchek9 , D. G. Evans10,11 , D. Fischerova 12 , N. Harbeck 13 , C. Kuhl 14 , B. Lemley 15,16 , E. Levy-Lahad 17 , M. Lambertini 18,19 , J. A. Ledermann20 , S. Loibl 21 , K.-A. Phillips 22 & S. Paluch-Shimon 23 , on behalf of the ESMO Guidelines Committee
doi : 10.1016/j.annonc.2022.10.004
Volume 34, Issue 1, January 2023, Pages 33-47
Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022
D. Araujo 1y, A. Greystoke2y, S. Bates3 , A. Bayle4 , E. Calvo 5 , L. Castelo-Branco6 , J. de Bono7,8 , A. Drilon 9 , E. Garralda 10 , P. Ivy 11 , O. Kholmanskikh 12,13 , I. Melero 14 , G. Pentheroudakis6 , J. Petrie15 , R. Plummer 2 , S. Ponce 4 , S. Postel-Vinay4 , L. Siu16 , A. Spreafico16 , A. Stathis 17 , N. Steeghs18 , C. Yap 7 , T. A. Yap 19 , M. Ratain 20 & L. Seymour 15
doi : 10.1016/j.annonc.2022.09.158
Volume 34, Issue 1, January 2023, Pages 48-60
Cancer: slaying the nine-headed Hydra
J. J. Adashek1* , V. Subbiah2 , C. B. Westphalen 3 , A. Naing 2 , S. Kato 4 & R. Kurzrock
doi : 10.1016/j.annonc.2022.07.010
Volume 34, Issue 1, January 2023, Pages 61-69
Streamlining clinical research: an ESMO awareness call to improve sponsoring and monitoring of clinical trials
J. L. Perez-Gracia 1* , N. Penel2 , E. Calvo3 , A. Awada 4 , H. T. Arkenau 5 , T. Amaral 6,7 , V. Grünwald 8 , M. F. Sanmamed 1 , L. Castelo-Branco9,10 , G. Bodoky11 , M. P. Lolkema 12 , M. Di Nicola13 , P. Casali 14 , R. Giuliani 15 & G. Pentheroudakis
doi : 10.1016/j.annonc.2022.09.162
Volume 34, Issue 1, January 2023, Pages 70-77
Short-term outcomes of chemoradiotherapy and local excision versus total mesorectal excision in T2-T3ab,N0,M0 rectal cancer: a multicentre randomised, controlled, phase III trial (the TAU-TEM study)
X. Serra-Aracil 1* , C. Pericay2 , J. Badia-Closa 1 , T. Golda 3 , S. Biondo3 , P. Hernández 4 , E. Targarona 4 , N. Borda-Arrizabalaga 5 , A. Reina6 , S. Delgado7 , F. Vallribera 8 , A. Caro9 , J. Gallego-Plazas 10 , M. Pascual 11 , C. �lvarez-Laso12 , H. G. Guadalajara-Labajo 13 & L. Mora-Lopez
doi : 10.1016/j.annonc.2022.09.160
Volume 34, Issue 1, January 2023, Pages 78-90
Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)—a randomized phase II trial of the AIO pancreatic cancer group
T. Seufferlein1*y, W. Uhl2y, M. Kornmann 3 , H. Algül4 , H. Friess 5 , A. König 6 , M. Ghadimi 7 , E. Gallmeier 8 , D. K. Bartsch9 , M. P. Lutz 10 , R. Metzger11 , K. Wille12 , B. Gerdes13 , C. C. Schimanski 14 , F. Graupe 15 , V. Kunzmann16 , I. Klein17 , M. Geissler 18 , L. Staib 19 , D. Waldschmidt 20 , C. Bruns 21 , U. Wittel22 , S. Fichtner-Feigl 22 , S. Daum23 , A. Hinke24 , L. Blome25 , A. Tannapfel 26 , A. Kleger1 , A. W. Berger1 , A. M. R. Kestler1 , J. S. Schuhbaur 1 , L. Perkhofer 1 , M. Tempero27 , A. C. Reinacher-Schick 28 & T. J. Ettrich
doi : 10.1016/j.annonc.2022.09.161
Volume 34, Issue 1, January 2023, Pages 91-100
Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial
Y. Tao 1y, J. Biau2y, X. S. Sun 3 , C. Sire4 , L. Martin 5 , M. Alfonsi 6 , J. B. Prevost7 , A. Modesto 8 , C. Lafond 9 , J. M. Tourani10 , J. Miroir2 , M. C. Kaminsky 11 , A. Coutte 12 , X. Liem13 , E. Chautard2 , E. Vauleon14 , F. Drouet 15 , A. Ruffier1,9 , J. F. Ramee 16 , G. Waksi 17 , A. Péchery 17 , M. Wanneveich17 , J. Guigay18 , A. Aupérin19 & J. Bourhis
doi : 10.1016/j.annonc.2022.10.006
Volume 34, Issue 1, January 2023, Pages 101-110
Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study
Z. R. Reichert 1 , T. M. Morgan1 , G. Li2 , E. Castellanos 3 , T. Snow 3 , F. G. Dall’Olio4,5 , R. W. Madison 2 , A. D. Fine 2 , G. R. Oxnard 2 , R. P. Graf 2 & D. G. Stover
doi : 10.1016/j.annonc.2022.09.163
Volume 34, Issue 1, January 2023, Pages 111-120
Potentially improved response of COVID-19 vaccinated nasopharyngeal cancer patients to combination therapy with anti-PD-1 blockade and chemotherapy
Y. J. Hua 1,y, Y. L. Liu 1,y, K. Wen 1 , C. Kurts 2 *, H. Wu 3 *, Q. Mei 4,5 * & J. Li
doi : 10.1016/j.annonc.2022.10.002
Volume 34, Issue 1, January 2023, Pages 121-123
VP7-2022: An ad-hoc interim overall survival results of niraparib with individualized starting dose as maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer (NORA): A double-blind, randomized, placebo-controlled, phase III trial
M. R. Mirza1, X. Wu 2 , J. Zhu 3 , R. Yin 4 , J. Yang 5 , J. Liu 6 , J. Wang 7 , L. Wu 8 , Z. Liu 9 , Y. Gao 10 , D. Wang 11 , G. Lou 12 , H. Yang 13 , Q. Zhou 14 , B. Kong 15 , Y. Huang 16 , L. Chen 17 , X. Zhen 18 , J. Dong 19 & J. Hou
doi : 10.1016/j.annonc.2022.11.007
Volume 34, Issue 1, January 2023, Pages 124-125
